Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy

Chun, 1997, Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy, PNAS, 94, 13193, 10.1073/pnas.94.24.13193

Chun, 1997, Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection, Nature, 387, 183, 10.1038/387183a0

Finzi, 1997, Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, 278, 1295, 10.1126/science.278.5341.1295

Blankson, 2002, The challenge of viral reservoirs in HIV-1 infection, Annu Rev Med, 53, 557, 10.1146/annurev.med.53.082901.104024

Eisele, 2012, Redefining the viral reservoirs that prevent HIV-1 eradication, Immunity, 37, 377, 10.1016/j.immuni.2012.08.010

Xing, 2013, Targeting HIV latency: pharmacologic strategies toward eradication, Drug Discov Today, 18, 541, 10.1016/j.drudis.2012.12.008

Archin, 2012, Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy, Nature, 487, 482, 10.1038/nature11286

Rasmussen, 2014, Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial, Lancet HIV, 1, e14, 10.1016/S2352-3018(14)70014-1

Elliott, 2014, Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy, PLoS Pathog, 10, e1004473, 10.1371/journal.ppat.1004473

Zhang, 1996, Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C, Cancer Res, 56, 802

Amador, 2003, Progress in the development and acquisition of anticancer agents from marine sources, Ann Oncol, 14, 1607, 10.1093/annonc/mdg443

Pérez, 2010, Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency, Curr HIV Res, 8, 418, 10.2174/157016210793499312

Plimack, 2014, A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma, Oncologist, 19, 354, 10.1634/theoncologist.2014-0020

Morgan, 2012, Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study, Invest New Drugs, 30, 723, 10.1007/s10637-010-9557-5

Smith, 2011, Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF, Leuk Res, 35, 87, 10.1016/j.leukres.2010.06.001

Pavlick, 2009, Phase I study of bryostatin-1, a protein kinase C modulator, preceding cisplatin in patients with refractory nonhematologic tumors, Cancer Chemother Pharmacol, 64, 803, 10.1007/s00280-009-0931-y

Ajani, 2006, A multicenter phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma, Invest New Drugs, 24, 353, 10.1007/s10637-006-6452-1

Zhao, 2005, Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry, Anal Biochem, 337, 143, 10.1016/j.ab.2004.10.030

Mehla, 2010, Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner, PLoS One, 5, e11160, 10.1371/journal.pone.0011160

Martínez-Bonet, 2015, Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal, Antiviral Res, 123, 163, 10.1016/j.antiviral.2015.09.014

Díaz, 2015, Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism, Sci Rep, 5, 12442, 10.1038/srep12442

Bullen, 2014, New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo, Nat Med, 20, 425, 10.1038/nm.3489

Laird, 2015, Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations, J Clin Invest, 125, 1901, 10.1172/JCI80142

El-Rayes, 2006, Phase I study of bryostatin 1 and gemcitabine, Clin Cancer Res, 12, 7059, 10.1158/1078-0432.CCR-06-1419

Lewin, 1999, Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy, J Virol, 73, 6099, 10.1128/JVI.73.7.6099-6103.1999

Fischer, 1999, Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues, J Clin Microbiol, 37, 1260, 10.1128/JCM.37.5.1260-1264.1999

Yukl, 2010, Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy, J Infect Dis, 202, 1553, 10.1086/656722

Varterasian, 1998, Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia, J Clin Oncol, 16, 56, 10.1200/JCO.1998.16.1.56

Jones, 1990, Bryostatin 1, a unique biologic response modifier: antileukemic activity in vitro, Blood, 75, 1319, 10.1182/blood.V75.6.1319.1319

Archin, 2014, HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat, J Infect Dis, 210, 728, 10.1093/infdis/jiu155

S⊘gaard, 2015, The depsipeptide romidepsin reverses HIV-1 latency in vivo, PLoS Pathog, 11, e1005142, 10.1371/journal.ppat.1005142

Reuse, 2009, Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection, PLoS One, 4, e6093, 10.1371/journal.pone.0006093

Martínet-Bonet, 2015, Synergistic activation of latent HIV-1 expression by novel histone deacetylase inhibitors and bryostatin-1, Sci Rep, 13, 16445, 10.1038/srep16445